Results 151 to 160 of about 101,700 (245)

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, Volume 117, Issue 4, Page 885-895, April 2026.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia. [PDF]

J Physiol Biochem
Hrdinova T, Kupcova Skalnikova H.
europepmc   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, Volume 117, Issue 4, Page 896-903, April 2026.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source

Simulation of Imatinib Pharmacokinetics in pregnant women with chronic myeloid leukemia in the third trimester. [PDF]

Eur J Clin Pharmacol
Mian P, Lok CAR, Dontje AEWK, Prins JR, Oude Munnink TH, Nieuwenhuizen L, Gordijn SJ, Touw DJ, Malik P.   +8 more
europepmc   +1 more source

Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling

Physiological Reports, Volume 14, Issue 8, April 2026.
Abstract As a widely used anticancer drug for the treatment of chronic myeloid leukemia, ponatinib is known to cause severe cardiovascular toxicities. Cardiomyocytes are the major functional units in the myocardium, and impairment of their viability and function plays a crucial role in cardiotoxic responses.
Linna Guo, Rongjia Rao, Hong Liu, Bingying Zhou   +3 more
wiley   +1 more source

Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma. [PDF]

J Manag Care Spec Pharm
Amamoo RS, Schuerman B, Obeng-Kusi M, Yun S, Erstad B, Abraham I.   +5 more
europepmc   +1 more source

Targeted Therapy for Advanced Gastrointestinal Stromal Tumors: Evolution and Future Directions. [PDF]

Drug Des Devel Ther
Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR.   +6 more
europepmc   +1 more source

Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center. [PDF]

Int J Mol Sci
Bota-Llorca A, Llombart-Cussac B, Serra-Guillén C, López-Guerrero JA, Traves V, Sanmartín-Martínez JJ, Requena C, Nagore E, Padilla-Esquivel J, Millán-Esteban D, Mayo F, Sanmartín O.   +11 more
europepmc   +1 more source

Imatinib and nilotinib are equally successful in achieving therapy-free remission. [PDF]

Blood Cancer J
Cheng F, Wang Y, Yang Y, Du X, Zhu Y, Weng J, Xu N, Huang J, Liu Z, Ren H, Zhao H, Zhu H, Jiang Q, Zhang Y, Li W.   +14 more
europepmc   +1 more source

Transcriptional readthrough precedes alternative splicing programs triggered in CML cells by imatinib. [PDF]

Sci Adv
Podszywałow-Bartnicka P, Shine M, Lin J, Neugebauer KM.   +3 more
europepmc   +1 more source